Document is current
Any future updates will be listed below
-
Authors
Garnier-Crussard, Antoine
Landeau, Brigitte
Mezenge, Florence
Gonneaud, Julie
Roquet, Daniel
Cotton, François
Chetelat, Gaël
-
Funding
Funding for this research was provided by:
Agence régionale de santé Auvergne-Rhône-Alpes
European Union’s Horizon 2020 Research and Innovation Program (667696, 667696)
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 6 October 2025
First Online: 3 November 2025
Declarations
:
: No disclosure to report.Independent of this work, A.G.-C. is an unpaid sub-investigator or local principal investigator in NCT04867616 (UCB Pharma), NCT04241068 (Biogen), NCT05310071 (Biogen), NCT03446001 (TauRx Therapeutics), NCT03444870 (Roche), NCT04374253 (Roche), NCT04777396 (Novo Nordisk), NCT04777409 (Novo Nordisk), NCT04770220 (Alzheon), NCT05423522 (Medesis Pharma), NCT06079190 (GlaxoSmithKline).Independent of this work, F.C. has received consulting and lecturing fees, travel grants and unconditional research support from Alexion, Biogen, Bracco, Guerbet, Philips Medical imaging, Novartis, Telediag and Roche.Independent of this work, G.C. has received research support from the European Union’s Horizon 2020 research and innovation programme (grant agreement number 667696), Fondation d’entreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Région Normandie, Association France Alzheimer et maladies apparentées, Fondation Vaincre Alzheimer, Fondation Recherche Alzheimer, Fondation Bettencourt Schueller and Fondation pour la Recherche Médicale (all to Inserm), and personal fees from Fondation Alzheimer and Lilly.
